ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

This study is currently recruiting participants.
Study NCT00568282.   Last updated on May 30, 2008.   Information provided by Stanford University

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Official Title  Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Brief Summary

The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Detailed Description

The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Study Phase
Study Type  Observational
Study Design  Prospective
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Lung Cancer
Intervention  Procedure: phlebotomy
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  100
Start Date  February 2007
Completion Date
Eligibility Criteria 

Inclusion Criteria:Inclusion Criteria (Cases):

  1. Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
  2. Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
  3. ability to sign informed consent
  4. at least 18 years of age

Inclusion Criteria (Controls):

  1. no known prior or active malignancy
  2. ability to sign informed consent
  3. at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years

2. pregnant women

Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00568282
Organization ID SU-11052007-804
Secondary IDs †† 96710, LUN0017, NCT00568282
Study Sponsor  Stanford University
Collaborators ††
Investigators 
Principal Investigator:     Heather A. Wakelee     Stanford University    
Information Provided By Stanford University
Verification Date May 2008
First Received Date  December 4, 2007
Last Updated Date May 30, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers